Neuromuscular electrical stimulation (NMES) was studied with positron emission tomography (PET) and H 2 15 O in the quadriceps muscle of 11 men. The subjects were submitted to simultaneous bilateral isometric contraction (5 s)-rest (5 s) cycles for 12 min, with a workload corresponding to 5% of quad
Pharmacokinetics of radiotracers in human plasma during positron emission tomography
β Scribed by Paul Cumming; Fuji Yokoi; Anjing Chen; Paul Deep; Alain Dagher; David Reutens; Flavio Kapczinski; Dean F. Wong; Albert Gjedde
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 225 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0887-4476
No coin nor oath required. For personal study only.
β¦ Synopsis
Many radiopharmaceuticals for positron emission tomography (PET) are substantially metabolized in peripheral organs. Pharmacological treatments intended to alter cerebral metabolism might also alter radiotracer metabolism, consequently altering the cerebral uptake. First-order rate constants for the metabolism of PET tracers can be calculated by a linear graphical method from the precursor and metabolite concentrations measured in plasma extracts fractionated by HPLC. We tested the effects of specific pharmacological challenges on the plasma kinetics of six tracers used for PET studies of neurotransmission. The rate of O-methylation of circulating [ 18 F]fluorodopa, a tracer of dopa decarboxylase activity in brain, was unaffected by pretreatment with amantadine, an antagonist of glutamate receptors. [ 11 C]Deprenyl, a tracer of monoamine oxidase activity, was rapidly metabolized to [ 11 C]methamphetamine and polar metabolites in healthy volunteers. The net rate constant of this metabolism was three times higher in a group of subjects under treatment for epilepsy, consistent with induction of hepatic microsomal enzymes by antiepileptic drugs. [ 11 C]Sch 23390, a ligand for dopamine D1 receptors, was rapidly metabolized to polar metabolites. The net rate constant of metabolism was unaffected by pretreatment with lorazepam. [ 11 C]-(S)-Nicotine, a ligand for nicotinic receptors, was rapidly metabolized to [ 11 C]-(S)-cotenine, which is less polar than the parent compound. Pretreatment with mazindol, a dopamine uptake inhibitor, was without effect on peripheral metabolism of [ 11 C]-(S)-nicotine.
[ 11 C]WIN 35,428, a tropane derivative which labels dopamine uptake sites, was metabolized to a nonpolar metabolite, but so slowly that the rate constant of this process could not be calculated. [ 11 C]Raclopride, a ligand for dopamine D2 receptors, was first metabolized to a nonpolar metabolite, which then yielded two hydrophilic metabolites. The initial metabolic step was substantially blocked by pretreatment with amphetamine, possibly indicative of competitive inhibition of microsomal oxidation. Together, these results indicate that the linear graphic method is useful for estimating the kinetics of the plasma metabolism of many widely used PET tracers. Drug-drug interactions were revealed in subjects treated with specific pharmacological agents prior to tracer administration.
π SIMILAR VOLUMES
The goal of the present set of studies was to characterize the in vitro binding properties and in vivo tissue kinetics for the vesicular acetylcholine transporter (VAcChT) radiotracer, [ 18 F](1)-4-fluorobenzyltrozamicol ([ 18 F](1)-FBT). In vitro binding studies were conducted in order to determine
The role of serotonin in CNS function and in many neuropsychiatric diseases (e.g., schizophrenia, affective disorders, degenerative dementias) support the development of a reliable measure of serotonin receptor binding in vivo in human subjects. To this end, the regional distribution and intrasubjec